Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a year ago

Possible Interaction: Cannabidiol and Cannabinoids

supplement:

Cannabidiol

supplement:

Cannabinoids

Research Papers that Mention the Interaction

These results suggest that the effects of CBD , as opposed to those of delta 9-THC, might be involved in the antagonism of effects between the two cannabinoids.
Psychopharmacology  •  1982  |  View Paper
Both in vivo and in vitro receptor mechanism studies indicate that CBD may act as a negative allosteric modulator of type 1 cannabinoid (CB1) receptor and an agonist of type 2 cannabinoid (CB2), transient receptor potential vanilloid 1 (TRPV1), and serotonin 5-HT1A receptors.
International journal of molecular sciences  •  2020  |  View Paper
CBD inhibitory effects on the NLRP3 inflammasome may contribute to the overall anti-inflammatory effects reported for this phytocannabinoid.
Journal of natural products  •  2020  |  View Paper
In terms of cannabidiol action , the phytocannabinoid altered the functional responses, likely by allosteric means, and modified potency, agonist IC50/EC50 values and biased agonism in qualitative and/or quantitative different ways depending on the agonist.
Biochemical pharmacology  •  2018  |  View Paper
Since co-abuse of opiates and cocaine with alcohol is common, the reported anti-reinstatement actions of CBD across three major classes of abused drugs further add to the putative treatment drug promise of this phytocannabinoid.
Neuropsychopharmacology  •  2018  |  View Paper
These major cannabinoids inhibited the 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) and dextromethorphan O-demethylase activities of recombinant CYP2D6 and pooled human liver microsomes in a concentration-dependent manner (IC50 = 4.01–24.9 μM), indicating the strongest inhibitory potency of CBD.
Drug Metabolism and Disposition  •  2011  |  View Paper
Here we tested the hypothesis that CBD anticonvulsant mechanisms are prevented by cannabinoid (CB1 and CB2) and vanilloid (TRPV1) receptor blockers.
Epilepsy & Behavior  •  2017  |  View Paper
Overall, our data suggest that CBD modulates hippocampal [Ca2+]i homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway.
Neuropharmacology  •  2006  |  View Paper
Previous experiments with the mouse vas deferens have shown that cannabidiol produces surmountable antagonism of cannabinoid CB(1 ) receptor agonists at concentrations well below those at which it binds to cannabinoid CB(1) receptors and antagonizes alpha(1)-adrenoceptor agonists insurmountably.
European journal of pharmacology  •  2004  |  View Paper
Acute cannabidiol treatment of mice inactivated hepatic microsomal cytochrome P-450IIIA (P-450IIIA) and markedly inhibited in vitro cannabinoid metabolism.
Molecular pharmacology  •  1991  |  View Paper
Show More